HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

15-hydroxyanandamide

structure in first source

Also Known As:

15-HAEA

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Bär, P R: 1 article (05/2003)
2.	Di Marzo, V: 1 article (05/2003)
3.	Fezza, F: 1 article (05/2003)
4.	Maccarrone, M: 1 article (05/2003)
5.	Nicolay, K: 1 article (05/2003)
6.	Veldhuis, W B: 1 article (05/2003)
7.	Veldink, G A: 1 article (05/2003)
8.	Vliegenthart, J F G: 1 article (05/2003)
9.	Wadman, M W: 1 article (05/2003)
10.	van Zadelhoff, G: 1 article (05/2003)

Related Diseases

1.

05/15/2003 - "Using magnetic resonance imaging we show the following: (1) pretreatment with the reduced 12-lipoxygenase metabolite of AEA, 12-HAEA, attenuated cytotoxic edema formation in a CB1 receptor-independent manner in the acute phase after intracranial injection of the Na+/K+-ATPase inhibitor ouabain; (2) the reduced 15-lipoxygenase metabolite, 15-HAEA, enhanced the neuroprotective effect of AEA in the acute phase; (3) modulation of VR1, as tested using arvanil, the VR1 agonist capsaicin, and the antagonist capsazepine, leads to neuroprotective effects in this model, and arvanil is a potent neuroprotectant, acting at both CB1 and VR1; and (4) the in vivo neuroprotective effects of AEA are mediated by CB1 but not by lipoxygenase metabolites or VR1."

Related Drugs and Biologics

1.	CB1 Cannabinoid Receptor (CB1 Receptor)
2.	Neuroprotective Agents
3.	Ouabain (G Strophanthin)
4.	Lipoxygenase (Lipoxygenase-1)
5.	Capsaicin (Zostrix)
6.	Arachidonate 15-Lipoxygenase (Arachidonate 15 Lipoxygenase)
7.	Arachidonate 12-Lipoxygenase (12 Lipoxygenase)
8.	ATPase Inhibitory Protein
9.	arvanil
10.	capsazepine